Wave Life Sciences USA, Inc.

Wave Life Sciences USA, Inc. is a biotechnology company that develops RNA medicines for severe genetic and other serious disorders. Its PRISM platform combines RNA editing, RNA splicing, RNA interference and antisense silencing with oligonucleotide chemistry and insights from human genetics, with the aim of addressing disease biology at its source. The company is headquartered in Cambridge, Massachusetts, and operates in the United States and internationally.

The company's diversified clinical pipeline spans several therapeutic areas. Candidates include WVE-007 for obesity, WVE-006 for alpha-1 antitrypsin deficiency and WVE-008 for PNPLA3 I148M liver disease, alongside programs for Duchenne muscular dystrophy and Huntington's disease. The underlying technical domains - RNA editing, splicing, interference and antisense silencing, together with oligonucleotide chemistry and human genetics - constitute the core areas of expertise across its research and clinical work.

Wave's stated approach is collaborative, involving work with scientists, clinical teams, patients and families around the world. The company describes its culture as mission-driven and focused on unmet medical need in genetic medicines, metabolic and liver disease, neurology and obesity.